Wherever people with chronic spinal cord injury (SCI) gather in veterans and civilian centers, colon and rectal surgeons are called as consultants to create colostomies for intractable constipation and/or incontinence and to treat the hemorrhoids that follow years of mechanically stimulated defecation. Occasionally, we are asked to comment on SCI bowel care, more commonly to manage slow-transit constipation and/or functional outlet obstruction. However, for some people with SCI, especially those with lower levels of injury (paraplegia rather than tetraplegia) and lower motor neuron dysfunction, fecal incontinence is a prominent feature of their neurogenic bowel. This may be managed by medical and mechanical bowel programs that replace the vagaries of spontaneous defecation with scheduled, stimulated evacuation, and by such surgical techniques as sacral nerve stimulation and antegrade irrigation via appendicostomy or cecostomy. A Cochrane review finds little compelling evidence for most current treatments and no way to compare them. This would suggest caution to enthusiasts of one or another treatment—and the more invasive the treatment, the more caution is advised.

Into this still-nascent, underresearched field comes a modest new medical entrant, the topical α-agonist oxymetazoline. The study published in this issue has what Cochrane evaluators would call high risk for bias because it is funded by a drug company and first authored by an employee and stockholder. That company, RDD Pharma (Tel Aviv, Israel), describes a business model of “repurposing drugs…that are already approved for other indications,” for anorectal disease. Readers may be familiar with oxymetazoline as the active agent in over-the-counter nasal decongestants (eg, Afrin, Bayer Consumer Health, Whippany, NJ), over-the-counter antiredness eye drops, and prescription topicals for rosacea.

Risk for bias notwithstanding, the study is a randomized crossover study of methodologically sound design in which 2 tetraplegics and 17 paraplegics, all of whom had significant incontinence as part of their neurogenic bowel pattern, were divided into 2 groups. The groups used 1% oxymetazoline gel or placebo gel intra-anally once a day for 4 weeks. After a 2-week washout, the 2 groups crossed over, each getting the other treatment. With each patient as his or her own control, resting anal pressure was higher and episodes of incontinence (gas and nongas) were fewer with oxymetazoline. Overall formal incontinence scores were not changed significantly.

A lingering concern about this study is the heterogeneous nature of the SCI patients, who had injuries at various levels, from differing etiologies, with differing levels of completeness of injury, and with (in all likelihood) widely differing, quite individual patterns of neurogenic bowel dysfunction. A randomly selected group of fecally incontinent people without SCI might well be more homogeneous than the SCI group tested here. This raises the question of why this study was performed in the SCI population. Is this a case of a therapy tailored specifically for people with SCI but that might later be of service to the general population? I do not see anything particularly SCI specific about the drug or mode of delivery. Alternatively, given their avowed penchant for repurposing, might RDD Pharma be angling for the general population, using the SCI indication as an easier route to regulatory approval? I will happily admit ignorance of how regulatory sausages are made, and the Talmudic principle of דעי לכף זכות (judge favorably or give the benefit of doubt) certainly applies here. People with SCI can use help with the incontinence.

Funding/Support: None reported.

Financial Disclosure: None reported.

Correspondence: Bard C. Cosman, M.D., M.P.H., VA San Diego Healthcare System, 3350 La Jolla Village Drive, #112E, San Diego, CA 92161-0002. E-mail: cosman@sbcglobal.net

DOI: 10.1097/DCR.0000000000001264
© The ASCRS 2019

aspect of their neurogenic bowel, and topical oxymetazo-
line might be of service. Absent scientific guidance, prac-
titioners of the art of SCI bowel care—people with SCI
and their caregivers—need more tools to supplement their
currently meager toolkit.

In his novel about how sausages were made, Upton
Sinclair figuratively "aimed for the public’s heart, and…
hit it in the stomach." Similar statements may be made
literally by the inventors of surgical robotics, who aimed
for the heart and hit the prostate, among other noncardiac
targets. Likewise, today’s fissure drugs, purposed for heart,
blood vessels, and extraocular muscles, later trickled down
to the anus, and the original synthesizers of oxymetazoline
in the 1960s probably did not envision the anal Afrin de-
scribed here. However, people on the front lines do what-
ever works with the materials at hand. Repurposed tools
are more than welcome.

REFERENCES
1. Bølling Hansen R, Staun M, Kalhauge A, Langholz E, Biering-
Sørensen F. Bowel function and quality of life after colosto-
2. Cosman BC, Cajas-Monson LC, Ramamoorthy SL. Twenty
years of a veterans’ spinal cord injury colorectal clinic: flexible
sigmoidoscopy and multiple hemorrhoid ligation. Dis Colon
Bowel dysfunction in patients with spinal cord injury: rela-
Sacral nerve stimulation for neurogenic faecal incontinence. Br
5. Gor RA, Katorski JR, Elliott SP. Medical and surgical manage-
6. Coggrave M, Norton C, Cody JD. Management of faecal in-
continence and constipation in adults with central neurological
7. Barak N, Gecse K, Tákas K. Topical oxymetazoline for fecal in-
continence in patients with spinal cord injury: a double-blind
Harcourt, Brace & World; 1962:126.